Brief: FDA Approves Obecabtagene Autoleucel For Adults With Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
08/11/2024 20:46
Nov 8 (Reuters) - FDA:
* FDA APPROVES OBECABTAGENE AUTOLEUCEL FOR ADULTS WITH
RELAPSED OR
REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
* FDA: APPROVES AUCATZYL FOR ADULTS WITH RELAPSED OR
REFRACTORY
B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
Further company coverage: 6A3Ay.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Autolus Therapeutics
See all newsBrief: Autolus Therapeutics PLC Unit Enters Master Service Agreement With AGC Biologics
Brief: Autolus Therapeutics Appoints Ryan Richardson To Board Of Directors
Brief: Nice Recommends Aucatzyl As A Treatment Option For Adult Patients With Lymphoblastic Leukemia
Brief: Autolus Therapeutics’ Car T Therapy Aucatzyl® (Obecabtagene Autoleucel) Granted European Marketing Authorization For Adult Patients
Brief: Autolus Therapeutics Announces Inducement Grants